eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) is a clinical-stage biopharmaceutical company that completed its business combination with Locust Walk Acquisition Corp., a blank-check vehicle sponsored by Locust Walk, in 2021. The company focuses on translation control therapeutics targeting the eIF4F complex as a mechanism to treat cancer, placing it within the oncology and biopharmaceutical sector. On June 23, 2023, eFFECTOR submitted an 8-K current report to the SEC under accession number 0001193125-23-173792, disclosing material corporate developments to shareholders. As of the filing date, the company remained an active publicly traded entity following its SPAC-driven public debut. Sign up for SpacDesk to access the complete filing history, sponsor profiles, and deal analytics for eFFECTOR and hundreds of other SPAC transactions.